Clinical Trials Browser

Withdrawn × Glioblastoma × Surveys and Questionnaires × Clear all

NCT01782976 2018-01-19

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Phase 2 Withdrawn

Glioblastoma, Recurrence